{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:11:27Z","timestamp":1777875087487,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-002 -074 -MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-002 -074 -MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007647","name":"National Taiwan University College of Medicine","doi-asserted-by":"publisher","award":["113C102-72"],"award-info":[{"award-number":["113C102-72"]}],"id":[{"id":"10.13039\/501100007647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jdermsci.2024.03.001","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T22:33:08Z","timestamp":1709677988000},"page":"44-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting antibody-mediated complement-independent mechanism in bullous pemphigoid with diacerein"],"prefix":"10.1016","volume":"114","author":[{"given":"Yung-Tsu","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Yi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Yu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2024.03.001_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2024.03.001_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jdermsci.2016.03.009","article-title":"High serum anti-BP180 IgE levels correlate to prominent urticarial lesions in patients with bullous pemphigoid","volume":"83","author":"Cho","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib3","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/1346-8138.16654","article-title":"What\u2019s new in the pathogeneses and triggering factors of bullous pemphigoid","volume":"50","author":"Ujiie","year":"2023","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2021.11.003","article-title":"The pathogenesis of pemphigus and pemphigoid diseases","volume":"104","author":"Ujiie","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment","volume":"129","author":"Iwata","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib7","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ajpath.2012.11.029","article-title":"Bullous pemphigoid IgG induces BP180 internalization via a macropinocytic pathway","volume":"182","author":"Hiroyasu","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fimmu.2019.00200","article-title":"Bullous pemphigoid IgG induces cell dysfunction and enhances the motility of epidermal keratinocytes via Rac1\/proteasome activation","volume":"10","author":"Tie","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib9","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib10","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.4049\/jimmunol.1003402","article-title":"Antibodies to pathogenic epitopes on Type XVII collagen cause skin fragility in a complement-dependent and -independent manner","volume":"188","author":"Natsuga","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.912876","article-title":"Insights into the pathogenesis of bullous pemphigoid: the role of complement-independent mechanisms","volume":"13","author":"Cole","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1523-1747.2000.00141.x","article-title":"Autantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes","volume":"115","author":"Schmidt","year":"2000","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109920","article-title":"Diacerein: a potential multi-target therapeutic drug for COVID-19","volume":"144","author":"Oliveira","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.jdermsci.2024.03.001_bib14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3389\/fphar.2016.00247","article-title":"A comprehensive and system review for the pharmacological mechanism of action of rhein, an active anthraquinone ingredient","volume":"7","author":"Sun","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1142\/S0192415X19500071","article-title":"Rhein, an anthraquinone drug, suppresses the NLRP3 inflammasome and macrophage activation in urate crystal-induced gouty inflammation","volume":"47","author":"Chang","year":"2019","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib16","doi-asserted-by":"crossref","first-page":"3313419","DOI":"10.1155\/2021\/3313419","article-title":"An update of anthraquinone derivatives emodin, diacerein, and catenarin in diabetes","volume":"2021","author":"Martorell","year":"2021","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib17","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jaad.2018.01.019","article-title":"Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2\/3 randomized, placebo-controlled, double blind clinical trial","volume":"78","author":"Wally","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-8-69","article-title":"Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study","volume":"8","author":"Wally","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00403-006-0690-0","article-title":"Localisation of bullous pemphigoid antigen 180 (BP180) in cultured human keratinocytes: functionally relevant modification by calcium","volume":"298","author":"Schmidt","year":"2006","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib20","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s12192-014-0513-8","article-title":"Hsp90 blockade modulates bullous pemphigoid IgG-induced IL-8 production by keratinocytes","volume":"19","author":"Tukaj","year":"2014","journal-title":"Cell Stress Chaperon."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib21","first-page":"1301","article-title":"Macropinocytosis of type XVII collagen induced by bullous pemphigoid IgG is regulated via protein kinase C. Lab","volume":"96","author":"Iwata","year":"2016","journal-title":"Investig"},{"key":"10.1016\/j.jdermsci.2024.03.001_bib22","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.1073\/pnas.1721805115","article-title":"BP180 dysfunction triggers spontaneous skin inflammation in mice","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jdermsci.2024.03.001_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jdermsci.2016.04.009","article-title":"Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid","volume":"83","author":"Fang","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib24","first-page":"102","article-title":"Serum levels of interleukin 18 and interleukin 10 in Iranian patients with bullous pemphigoid and their correlation with BP180-NC16a and BP230","volume":"19","author":"Esmaili","year":"2020","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/exd.14209","article-title":"Distinct compartmentalization of immune cells and mediators characterizes bullous pemphigoid disease","volume":"29","author":"Margaroli","year":"2020","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40520-018-0911-3","article-title":"Diacerein-containing products: same risk of diarrhea?","volume":"30","author":"Pelletier","year":"2018","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib27","article-title":"Rhein: a review of pharmacological activities","author":"Zhou","year":"2015","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.03.001_bib29","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40257-022-00688-x","article-title":"Clinical effectiveness and safety of initial combination therapy with corticosteroids and rituximab in bullous pemphigoid: a retrospective cohort study","volume":"23","author":"Tsai","year":"2022","journal-title":"Am. J. Clin. Dermatol."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181124000331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181124000331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:58:14Z","timestamp":1777582694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181124000331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0923181124000331"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2024.03.001","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting antibody-mediated complement-independent mechanism in bullous pemphigoid with diacerein","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2024.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}